Meldungen zum Thema Health

Folgen
Keine Meldung zum Thema Health mehr verpassen.
Filtern
  • 19.08.2004 – 14:11

    Inion Ltd

    Inion Receives FDA Clearance for Trinion Meniscus Screw

    Tampere, Finland (ots/PRNewswire) - Inion, one of the leading companies in the field of developing biodegradable medical implants, announces FDA 510(k) clearance of its Trinion(TM) Meniscus Screw for use in knee cartilage repair. This clearance allows Inion's Trinion(TM) screws to be marketed and sold in the US, complementing the previously offered HexalonTM biodegradable cruciate ligament repair screw, in the world's ...

  • 13.08.2004 – 19:03

    Quintiles Transnational Corp.

    Quintiles Reports 2nd Quarter Net Revenue of $426 Million

    Research Triangle Park, North Carolina (ots/PRNewswire) - - Strong net new business growth, up 31% for first half of 2004 - Fourth consecutive half-year increase in total net new business wins Quintiles Transnational Corp. today announced financial results for the quarter ended June 30, 2004. Net revenue for second quarter 2004 was US$425.8 million versus US$408.4 million for the same period in 2003. Net ...

  • 11.08.2004 – 08:08

    IsoTis OrthoBiologics

    /OFF HOLD OFF HOLD OFF HOLD -- IsoTis OrthoBiologics/

    Lausanne, Switzerland and Irvine, California (ots/PRNewswire) - Please add the following ticker symbols to the first paragraph of the release. (SWX/Euronext: ISO; TSX: ISO; Reuters: ISON.S; Reuters: ISO.TO; ASX: ISON.AS) IsoTis OrthoBiologics (SWX/Euronext: ISO; TSX: ISO; Reuters: ISON.S; Reuters: ISO.TO; ASX: ISON.AS) today reported a 16% increase in orthobiologics sales of US$12.9 million for the first six ...

  • 11.08.2004 – 07:40

    IsoTis OrthoBiologics

    /ON HOLD ON HOLD ON HOLD -- IsoTis OrthoBiologics/

    /ON HOLD ON HOLD ON HOLD -- IsoTis OrthoBiologics, EDB1011437 Please place the following release: "IsoTis Announces 16% H1 Orthobiologics Sales Growth, and Provides Further 04 & 05 Guidance" ON HOLD. ots Originaltext: IsoTis OrthoBiologics Im Internet recherchierbar: http://www.newsaktuell.ch Contact: Hans Herklots, +41-21-620-6011, Fax: +41-21-620-6060, hans.herklots@isotis.com, or Louis G. Plourde, ...

  • 11.08.2004 – 07:37

    IsoTis OrthoBiologics

    IsoTis Announces 16% H1 Orthobiologics Sales Growth, and Provides Further 04 & 05 Guidance

    Lausanne, Switzerland and Irvine, California (ots/PRNewswire) - IsoTis OrthoBiologics (SWX/Euronext: ISON; TSX: ISO) today reported a 16% increase in orthobiologics sales of US$12.9 million for the first six months of fiscal 2004, compared to pro-forma orthobiologics sales of US$11.1 million for the first six months of 2003. Sales for the second quarter 2004 were ...

  • 03.08.2004 – 08:58

    PROMETIC LIFE SCIENCES INC.

    ProMetic, The American Red Cross and Macopharma to Market the First Product for the Selective Adsorption of Prions out From Blood and Blood Derivatives

    Cambridge, England, Montreal, Canada. Washington D.c. and Lille, France (ots/PRNewswire) - - Initial European Roll out Planned for 2005 - Strategic Alliance to Include Development of Filters for Viruses - MacoPharma to Market and Distribute the Products - Financial Arrangement Based on Revenue ...

  • 07.07.2004 – 14:03

    Isotechnika Inc.

    FDA Grants Permission to Isotechnika for TAFA-93 Clinical Trial

    EDMONTON, Canada, July 7 (ots/PRNewswire) - Isotechnika Inc. today announced that the Company has received permission from the Food and Drug Administration of the United States for the commencement of a Phase Ib human clinical trial for TAFA-93. TAFA-93 is a novel prodrug of the mTOR inhibitor rapamycin designed to reduce the unfavourable pharmacokinetics ...

  • 06.07.2004 – 14:13

    Isotechnika Inc.

    Positive Data From Trans-ISA247 Single Ascending Dose Trial

    EDMONTON, Canada, July 6 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today the completion of the single ascending dose trial for the Company's lead immunosuppressive drug candidate, ISA247. The SAD trial was conducted in healthy volunteers using the trans-ISA247 formulation to assess the appropriate dosage of the enhanced composition of the drug. The data confirms that the trans formulation of ...

  • 01.07.2004 – 16:11

    SuperGen, Inc.

    SuperGen Submits Application for EMEA Approval of Orathecin

    DUBLIN, California, July 1 (ots/PRNewswire) -- - EuroGen Subsidiary Seeks Centralized Review for Pancreatic Cancer Treatment SuperGen, Inc. (Nasdaq: SUPG) announced today that a Marketing Authorization Application (MAA) seeking approval of Orathecin(TM) (rubitecan) Capsules has been submitted to the European Agency for the Evaluation of Medicinal Products (EMEA). Orathecin is the Company's investigational oral ...

  • 24.06.2004 – 18:12

    Unilabs SA

    Unilabs consolidates its position with the hospitals of the Vaud Riviera

    Geneva (ots) - The hospitals of the Vaud Riviera (Montreux Hospital and Hôpital du Samaritain in Vevey) have just extended their partnership with Unilabs until 2011 by adding a new partner, the Hôpital de la Providence in Vevey. The signature of this agreement confirms the excellent collaboration started in June 2000 with the Hôpital Riviera. The contract ...

  • 09.06.2004 – 07:00

    Unilabs SA

    UNILABS launches a new range of early-stage diagnostic tests in Europe

    Geneva (ots) - Biocheckup tests will allow early detection of signs of illness and permit evaluation of the risk factors for diseases such as diabetes, cancer or cardiovascular disease Most people are concerned by the state of their health and would like to know their predisposition to different pathologies before they become established (e.g. diabetes, cancer, ...

  • 01.06.2004 – 12:10

    Nat. Council of State Boards Nursing

    NCSBN Selects First Three Countries to Offer NCLEX Abroad

    CHICAGO, IL (ots) - The National Council of State Boards of Nursing (NCSBN) at www.ncsbn.org has selected the first three countries for purposes of offering the NCLEX examinations abroad for domestic nurse licensure purposes. NCSBN's Board of Directors affirmed the decision at its May meeting upon recommendation from the NCSBN Examination Committee. NCLEX testing is expected to begin January 2005 in Seoul, South Korea; ...

  • 01.03.2004 – 13:10

    Novo Nordisk

    Switzerland is first to launch new diabetes therapy - Levemir® (insulin detemir)

    Geneva (ots) - Novo Nordisk Switzerland announced today that Levemir® (insulin detemir), a novel, predictable basal insulin analogue with a unique mechanism of prolonging action (scientifically known as protraction), is available for people with type 1 and type 2 diabetes in Switzerland today. The Swiss launch is just the beginning of an exciting global roll-out of ...

  • 20.02.2004 – 14:52

    Human Kinetics

    The Classic Text Returns - Physiology Of Sport And Exercise, 3rd Edition

    Leeds (ots) - The completely updated version of the classic text captures the latest significant research findings in a reader-friendly format. Designed to more effectively meet the needs of students, this edition continues to make learning easy and enjoyable with chapter overviews, detailed figures, key terms, study questions, references, and an updated glossary ...

  • 03.12.2003 – 17:32

    Omron Healthcare Europe B.V.

    Omron Campaign Helps You to Get Healthy and Enjoy Your Life!

    Hoofdorp, The Netherlands (ots) - To help people improve their lifestyle and encourage healthy living and eating habits, Omron Healthcare Europe has launched "Enjoy your Life", a new section on its website. The new section offers people the chance to learn about how to improve their diet in order to maintain or improve their health. "At Omron, we believe that nutrition is highly important for healthy ...